The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Apollo Endosurgery P/E ratio is -5.61. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Apollo Endosurgery’s P/E ratio
What is Apollo Endosurgery P/E Ratio?
Apollo Endosurgery’s P/E ratio is -5.61, which represents a 69.33 % increase over the same period last year. their average P/E ratio is -9.73 and their 5-year average is -4.93.
What is Apollo Endosurgery Net EPS?
Apollo Endosurgery’s net earnings for the last quarter were -0.72$, which represents a 38.46% decrease from the same period last year.
Who are Apollo Endosurgery Competitors?
Based on Jika.io AI model, Amplitude Surgical SA, AVITA Medical, Electromed, PAVmed, Profound Medical Corp., SANUWAVE Health, TELA Bio, Vapotherm are considered to be Apollo Endosurgery’s competitors because the companies operate within the same industry as Apollo Endosurgery and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Apollo Endosurgery.
Who is Apollo Endosurgery’s Biggest competitor?
Apollo Endosurgery’s biggest competitor is Amplitude Surgical SA, based on the Jika.io AI model. it has a similar market capitalization to Apollo Endosurgery within the industry, it dominates a similar share of the market as Apollo Endosurgery, and it provides and markets very similar services.
What industry is Apollo Endosurgery in?
Apollo Endosurgery is part of the Medical Devices and Healthcare industry.
Apollo Endosurgery vs Amplitude Surgical SA
Market Cap: Apollo Endosurgery’s Market Cap of 162209120 is higher than Amplitude Surgical SA Market Cap of 136859280.
Average Volume: Apollo Endosurgery’s Average Volume of 120721.0 is lower than Amplitude Surgical SA Average Volume of 2064.0.
Beta: Apollo Endosurgery’s Beta of 2.29 is higher than Amplitude Surgical SA Beta of 0.68.
Revenue: Apollo Endosurgery’s Revenue of 62.989M is lower than Amplitude Surgical SA Revenue of 95.502M.
Net Income: Apollo Endosurgery’s Net Income of -24.682M is higher than Amplitude Surgical SA Net Income of -14.099M.
Gross Profit: Apollo Endosurgery’s Gross Profit of 34.959M is lower than Amplitude Surgical SA Gross Profit of 74.159M.
Ebitda: Apollo Endosurgery’s Ebitda of -12.976M is lower than Amplitude Surgical SA Ebitda of 16.15M.
P/E Ratio: Apollo Endosurgery’s P/E Ratio of -5.61 is lower than Amplitude Surgical SA P/E Ratio of -9.6.
P/S Ratio: Apollo Endosurgery’s P/S Ratio of 2.43 is higher than Amplitude Surgical SA P/S Ratio of 1.54.
P/B Ratio: Apollo Endosurgery’s P/B Ratio of 2.9 is higher than Amplitude Surgical SA P/B Ratio of 2.44.
P/FCF Ratio: Apollo Endosurgery’s P/FCF Ratio of -7.78 is lower than Amplitude Surgical SA P/FCF Ratio of 51.69.
ROE: Apollo Endosurgery’s ROE of -0.96 is higher than Amplitude Surgical SA ROE of -0.22.
ROA: Apollo Endosurgery’s ROA of -0.23 is higher than Amplitude Surgical SA ROA of -0.05.
Return On Capital Employed: Apollo Endosurgery’s Return On Capital Employed of -0.2 is lower than Amplitude Surgical SA Return On Capital Employed of 0.0.
Gross Profit Margin: Apollo Endosurgery’s Gross Profit Margin of 0.56 is lower than Amplitude Surgical SA Gross Profit Margin of 0.83.
Assets (Total): Apollo Endosurgery’s Assets (Total) of 131.528M is lower than Amplitude Surgical SA Assets (Total) of 269.072M.
Apollo Endosurgery vs AVITA Medical
Market Cap: Apollo Endosurgery’s Market Cap of 162209120 is lower than AVITA Medical Market Cap of 249556000.
Average Volume: Apollo Endosurgery’s Average Volume of 120721.0 is lower than AVITA Medical Average Volume of 350.0.
Beta: Apollo Endosurgery’s Beta of 2.29 is higher than AVITA Medical Beta of 0.73.
Revenue: Apollo Endosurgery’s Revenue of 62.989M is higher than AVITA Medical Revenue of 29.232M.
Net Income: Apollo Endosurgery’s Net Income of -24.682M is lower than AVITA Medical Net Income of -26.583M.
Gross Profit: Apollo Endosurgery’s Gross Profit of 34.959M is higher than AVITA Medical Gross Profit of 23.283M.
Ebitda: Apollo Endosurgery’s Ebitda of -12.976M is lower than AVITA Medical Ebitda of -25.808M.
P/E Ratio: Apollo Endosurgery’s P/E Ratio of -5.61 is higher than AVITA Medical P/E Ratio of -4.44.
P/S Ratio: Apollo Endosurgery’s P/S Ratio of 2.43 is lower than AVITA Medical P/S Ratio of 7.77.
P/B Ratio: Apollo Endosurgery’s P/B Ratio of 2.9 is higher than AVITA Medical P/B Ratio of 2.55.
P/FCF Ratio: Apollo Endosurgery’s P/FCF Ratio of -7.78 is lower than AVITA Medical P/FCF Ratio of -8.73.
ROE: Apollo Endosurgery’s ROE of -0.96 is higher than AVITA Medical ROE of -0.73.
ROA: Apollo Endosurgery’s ROA of -0.23 is lower than AVITA Medical ROA of -0.53.
Return On Capital Employed: Apollo Endosurgery’s Return On Capital Employed of -0.2 is lower than AVITA Medical Return On Capital Employed of -0.27.
Gross Profit Margin: Apollo Endosurgery’s Gross Profit Margin of 0.56 is lower than AVITA Medical Gross Profit Margin of 0.79.
Assets (Total): Apollo Endosurgery’s Assets (Total) of 131.528M is higher than AVITA Medical Assets (Total) of 125.501M.
Debt (Total): Apollo Endosurgery’s Debt (Total) of 53.573M is lower than AVITA Medical Debt (Total) of 878000.0.
Apollo Endosurgery vs Electromed
Market Cap: Apollo Endosurgery’s Market Cap of 162209120 is higher than Electromed Market Cap of 81554920.
Average Volume: Apollo Endosurgery’s Average Volume of 120721.0 is lower than Electromed Average Volume of 9140.0.
Beta: Apollo Endosurgery’s Beta of 2.29 is higher than Electromed Beta of 0.59.
Revenue: Apollo Endosurgery’s Revenue of 62.989M is higher than Electromed Revenue of 35.756M.
Net Income: Apollo Endosurgery’s Net Income of -24.682M is lower than Electromed Net Income of 2.362M.
Gross Profit: Apollo Endosurgery’s Gross Profit of 34.959M is higher than Electromed Gross Profit of 27.305M.
Ebitda: Apollo Endosurgery’s Ebitda of -12.976M is lower than Electromed Ebitda of 3.777M.
P/E Ratio: Apollo Endosurgery’s P/E Ratio of -5.61 is lower than Electromed P/E Ratio of 36.85.
P/S Ratio: Apollo Endosurgery’s P/S Ratio of 2.43 is higher than Electromed P/S Ratio of 2.03.
P/B Ratio: Apollo Endosurgery’s P/B Ratio of 2.9 is higher than Electromed P/B Ratio of 2.38.
P/FCF Ratio: Apollo Endosurgery’s P/FCF Ratio of -7.78 is lower than Electromed P/FCF Ratio of -85.92.
ROE: Apollo Endosurgery’s ROE of -0.96 is lower than Electromed ROE of 0.07.
ROA: Apollo Endosurgery’s ROA of -0.23 is lower than Electromed ROA of 0.06.
Return On Capital Employed: Apollo Endosurgery’s Return On Capital Employed of -0.2 is lower than Electromed Return On Capital Employed of 0.09.
Gross Profit Margin: Apollo Endosurgery’s Gross Profit Margin of 0.56 is lower than Electromed Gross Profit Margin of 0.76.
Assets (Total): Apollo Endosurgery’s Assets (Total) of 131.528M is lower than Electromed Assets (Total) of 37.109M.
Debt (Total): Apollo Endosurgery’s Debt (Total) of 53.573M is higher than Electromed Debt (Total) of 0.0.
Shareholders Equity: Apollo Endosurgery’s Shareholders Equity of 61.237M is higher than Electromed Shareholders Equity of 32.416M.
Apollo Endosurgery vs PAVmed
Market Cap: Apollo Endosurgery’s Market Cap of 162209120 is higher than PAVmed Market Cap of 83724944.
Average Volume: Apollo Endosurgery’s Average Volume of 120721.0 is higher than PAVmed Average Volume of 1.687M.
Beta: Apollo Endosurgery’s Beta of 2.29 is higher than PAVmed Beta of 0.24.
Revenue: Apollo Endosurgery’s Revenue of 62.989M is higher than PAVmed Revenue of 500000.0.
Net Income: Apollo Endosurgery’s Net Income of -24.682M is lower than PAVmed Net Income of -50.63M.
Gross Profit: Apollo Endosurgery’s Gross Profit of 34.959M is higher than PAVmed Gross Profit of -85000.0.
Ebitda: Apollo Endosurgery’s Ebitda of -12.976M is lower than PAVmed Ebitda of -56.046M.
P/E Ratio: Apollo Endosurgery’s P/E Ratio of -5.61 is higher than PAVmed P/E Ratio of -1.36.
P/S Ratio: Apollo Endosurgery’s P/S Ratio of 2.43 is higher than PAVmed P/S Ratio of 115.07.
P/B Ratio: Apollo Endosurgery’s P/B Ratio of 2.9 is higher than PAVmed P/B Ratio of 1.73.
P/FCF Ratio: Apollo Endosurgery’s P/FCF Ratio of -7.78 is higher than PAVmed P/FCF Ratio of -1.82.
ROE: Apollo Endosurgery’s ROE of -0.96 is lower than PAVmed ROE of -1.25.
ROA: Apollo Endosurgery’s ROA of -0.23 is lower than PAVmed ROA of -0.69.
Return On Capital Employed: Apollo Endosurgery’s Return On Capital Employed of -0.2 is lower than PAVmed Return On Capital Employed of -0.98.
Gross Profit Margin: Apollo Endosurgery’s Gross Profit Margin of 0.56 is higher than PAVmed Gross Profit Margin of -0.38.
Assets (Total): Apollo Endosurgery’s Assets (Total) of 131.528M is lower than PAVmed Assets (Total) of 86.976M.
Debt (Total): Apollo Endosurgery’s Debt (Total) of 53.573M is higher than PAVmed Debt (Total) of 0.0.
Shareholders Equity: Apollo Endosurgery’s Shareholders Equity of 61.237M is lower than PAVmed Shareholders Equity of 61.666M.
About Apollo Endosurgery
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development and commercialization of medical devices. the company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to suture and secure tissue approximation through flexible endoscopes. it also provides Orbera, an intragastric balloon system that reduces stomach capacity, causing patients to consume less after the procedure, and delays the emptying of gastric contents under the brands Orbera Intragastric Balloon System, BIB and Orbera365 Managed Weight Loss System. the company also offers the X-Tack Endoscopic HeliX Tacking System, a suture-based device for the closure and healing of defects in the lower and upper gastrointestinal tract. the company sells its products to medical services providers, hospitals, outpatient surgical centers, clinics and physicians in the United States, Australia, Costa Rica and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
